FINWIRES · TerminalLIVE
FINWIRES

$VERU

3 stories mentioning VERUUpdated 47d ago

Every FINWIRES story that references VERU, newest first.

What's the latest news on VERU?

Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) advanced 0.7%.In corporate news, Forte Biosciences (FBRX) shares soared 39% after it agreed to be acquired by Argenx (ARGX) in a deal worth about $2.2 billion. Argenx shares were down 2.5%.AstraZeneca (AZN) shares were up 0.8% after it posted higher Q2 core earnings and revenue, and raised its interim dividend.Ensign (ENSG) shares climbed nearly 3% after it reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Veru (VERU) said Monday it has completed enrollment in a phase 2 trial evaluating its experimental drug enobosam in combination with semaglutide, in about 200 adults aged 65 and older with obesity. Veru shares gained 3.1%.

$ARGX$AZN$ENSG$FBRX$VERU
Wire

Sector Update: Healthcare

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) advanced 0.7%.In corporate news, Veru (VERU) said Monday it has completed enrollment in a phase 2 trial evaluating its experimental drug enobosam in combination with semaglutide, in about 200 adults aged 65 and older with obesity. Veru shares gained 4.9%.

$VERU
Wire

Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge

Veru (VERU) said Thursday in a regulatory filing that it entered a clinical supply agreement with Novo Nordisk (NVO) to support its phase 2b PLATEAU study evaluating enobosarm in combination with Novo's Wegovy in older adults with obesity undergoing weight loss treatment.Under the agreement, Novo Nordisk will provide Wegovy free of charge for the study, while Veru will sponsor and conduct the trial and share clinical study updates and insights related to obesity and weight management research, the filing shows.Veru said it retains global development and commercialization rights to enobosarm, while Novo Nordisk received a right of first negotiation if Veru seeks to develop, commercialize or license enobosarm in combination with Novo Nordisk GLP-1 products in the future.Shares of Veru rose 155% in Thursday trading.Price: $5.52, Change: $+3.27, Percent Change: +145.47%

$NVO$VERU

Track with the FINWIRES app suite